


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Patent Application of

GABERT

Atty. Ref.: 1721-21

Serial No. 09/530,363

Group: 1656

Filed: May 1, 2000

Examiner: Spiegler

For: **METHOD FOR DIAGNOSING IN VITRO PATHOLOGIES
ASSOCIATED WITH GENE ARRANGEMENTS AND
DIAGNOSIS KITS**

TECH CENTER 1600/2900
REC'D
DEC 27 2001

December 26, 2001

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

AMENDMENT UNDER RULE 116

Responsive to the Official Action dated September 25, 2001, entry and consideration of the following amendments and remarks are requested.

IN THE SPECIFICATION

Amend the specification as follows.

Page 21, delete the paragraph on line 16 and insert the following therefor:

--(SEQ ID NO 2, 44 nucleotides, Tm = 84°C).--

Page 21, delete the paragraph on line 26 and insert the following therefor:

--(SEQ ID NO 3, 32 nucleotides, Tm = 84°C), and--

Page 21, delete the paragraph on line 33 and insert the following therefor:

--(SEQ ID NO 4, 29 nucleotides, Tm = 86°C), and--

Page 22, delete the paragraph on line 33 and insert the following therefor:

Corres. and Mail

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX AF



105b
AT

RESPONSE UNDER RULE 116
EXPEDITED HANDLING PROCEDURES

In re Patent Application of
GABERT
Serial No. 09/530,363
Filed: May 1, 2000
Title: METHOD FOR DIAGNOSING IN VITRO PATHOLOGIES
ASSOCIATED WITH GENE ARRANGEMENTS AND DIAGNOSIS
KITS

Atty Dkt. 1721-21
C#/M#
Group Art Unit: 1656
Examiner: Spiegler
Date: December 26, 2001

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

RESPONSE/AMENDMENT/LETTER

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

Fees are attached as calculated below:

Total effective claims after amendment	0	minus highest number		
Previously paid for	20	(at least 20) =	0	\$ 18.00
Independent claims after amendment	0	minus highest number		
Previously paid for	3	(at least 3) =	0	\$ 84.00
If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper)				
Petition is hereby made to extend the current due date so as to cover the filing date of this Paper and attachment(s) (\$110.00/1 month; \$400.00/2 months; \$920.00/3 months)				
Terminal disclaimer enclosed, add \$ 110.00				
First submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$740.00)				
Second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$740.00)				

Please enter the previously unentered , filed

SUBTOTAL \$ 0.00

If "small entity," then enter half (1/2) of subtotal and subtract
 Statement filed herewith

Rule 56 Information Disclosure Statement Filing Fee (\$180.00)

-\$ 0.00

Assignment Recording Fee (\$40.00)

\$ 0.00

TOTAL FEE ENCLOSED \$ 0.00

The Commissioner is hereby authorized to charge any deficiency in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100
BJS:1

NIXON & VANDERHYE P.C.
By Atty.: B. J. Sadoff, Reg. No. 36,663

Signature: 

RECEIVED
TECH CENTER 1600/2900
DEC 27 2001

GABERT
Serial No. 09/530,363

--(SEQ ID NO 5, 35 nucleotides, Tm = 81°C).--

Page 23, delete the paragraph spanning lines 5-6 and insert the following
therefor:

-- - ribozyme 1: CUCCAGCUGA UGAGUCCGUG AGGACGAAAC CUUUGG
(SEQ ID NO 6)--

Page 23, delete the paragraph spanning lines 8-9 and insert the following
therefor:

-- - ribozyme 2: CUGGAAUCUG AUGAGUCCGU GAGGACGAAA UUUUCUUC
(SEQ ID NO 7)--

IN THE CLAIMS

Amend the claims as follows:

Cancel claim 16, without prejudice

17. (Amended) The method of claim 39, wherein the primers consist of 25 to 40
nucleotides.

18. (Amended) The method of claim 39, further comprising, labeling said PCR
products, denaturing said labeled PCR products, and contacting the denatured labeled
PCR products with a nucleotide sequence complementary to a fusion partner nucleotide
sequence.